Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44


Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes.

Nene S, Gonczi L, Kurti Z, Morin I, Chavez K, Verdon C, Reinglas J, Kohen R, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

World J Gastroenterol. 2020 Feb 21;26(7):759-769. doi: 10.3748/wjg.v26.i7.759.


Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.

Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

Dig Dis Sci. 2019 Dec 7. doi: 10.1007/s10620-019-05982-z. [Epub ahead of print]


High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance.

Singh K, Al Khoury A, Kurti Z, Gonczi L, Reinglas J, Verdon C, Kohen R, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

J Crohns Colitis. 2019 Sep 27;13(10):1343-1350. doi: 10.1093/ecco-jcc/jjz066.


Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease.

Chao CY, Lemieux C, Restellini S, Afif W, Bitton A, Lakatos PL, Wild G, Bessissow T.

Saudi J Gastroenterol. 2019 May-Jun;25(3):159-166. doi: 10.4103/sjg.SJG_566_18.


Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre.

Gonczi L, Kurti Z, Verdon C, Reinglas J, Kohen R, Morin I, Chavez K, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

J Crohns Colitis. 2019 Sep 19;13(9):1138-1147. doi: 10.1093/ecco-jcc/jjz035.


Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic.

Reinglas J, Restellini S, Gonczi L, Kurti Z, Verdon C, Nene S, Kohen R, Afif W, Bessissow T, Wild G, Seidman E, Bitton A, Lakatos PL.

Dig Liver Dis. 2019 Mar;51(3):340-345. doi: 10.1016/j.dld.2018.11.013. Epub 2018 Dec 3.


Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review.

Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1265-1275.e8. doi: 10.1016/j.cgh.2018.12.021. Epub 2018 Dec 21. Review.


Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.

Saroli Palumbo C, Restellini S, Chao CY, Aruljothy A, Lemieux C, Wild G, Afif W, Lakatos PL, Bitton A, Cocciolillo S, Ghali P, Bessissow T, Sebastiani G.

Inflamm Bowel Dis. 2019 Jan 1;25(1):124-133. doi: 10.1093/ibd/izy200.


Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.

Restellini S, Chao CY, Lakatos PL, Aruljothy A, Aziz H, Kherad O, Bitton A, Wild G, Afif W, Bessissow T.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1531-1538. doi: 10.1093/ibd/izy044.


Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers.

Kopylov U, Nemeth A, Koulaouzidis A, Makins R, Wild G, Afif W, Bitton A, Johansson GW, Bessissow T, Eliakim R, Toth E, Seidman EG.

Inflamm Bowel Dis. 2015 Jan;21(1):93-100. doi: 10.1097/MIB.0000000000000255.


Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis.

Villani AC, Lemire M, Louis E, Silverberg MS, Collette C, Fortin G, Nimmo ER, Renaud Y, Brunet S, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Rioux JD, Arnott ID, Wild GE, Rutgeerts P, Satsangi J, Vermeire S, Hudson TJ, Franchimont D.

PLoS One. 2009 Sep 28;4(9):e7154. doi: 10.1371/journal.pone.0007154.


Phenotypic and genotypic characteristics of inflammatory bowel disease in French Canadians: comparison with a large North American repository.

Bhat M, Nguyen GC, Pare P, Lahaie R, Deslandres C, Bernard EJ, Aumais G, Jobin G, Wild G, Cohen A, Langelier D, Brant S, Dassopoulos T, McGovern D, Torres E, Duerr R, Regueiro M, Silverberg MS, Steinhart H, Griffiths AM, Elkadri A, Cho J, Proctor D, Goyette P, Rioux J, Bitton A.

Am J Gastroenterol. 2009 Sep;104(9):2233-40. doi: 10.1038/ajg.2009.267. Epub 2009 Jun 9. Erratum in: Am J Gastroenterol. 2010 Oct;105(10):2308.


Dexamethasone and GLP-2 given to lactating rat dams influence glucose uptake in suckling and postweanling offspring.

Drozdowski L, Iordache C, Clandinin MT, Wild G, Todd Z, Thomson AB.

JPEN J Parenter Enteral Nutr. 2009 Jul-Aug;33(4):433-9. doi: 10.1177/0148607108324874. Epub 2008 Dec 22.


Maternal dexamethasone and GLP-2 have early effects on intestinal sugar transport in their suckling rat offspring.

Drozdowski LA, Iordache C, Clandinin MT, Todd Z, Gonnet M, Wild G, Uwiera RR, Thomson AB.

J Nutr Biochem. 2009 Oct;20(10):771-82. doi: 10.1016/j.jnutbio.2008.07.006. Epub 2008 Nov 6.


Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370-7. doi: 10.1016/j.cgh.2008.06.007. Epub 2008 Oct 1. Erratum in: Clin Gastroenterol Hepatol. 2009 Apr;7(4):494.


Dexamethasone and GLP-2 administered to rat dams during pregnancy and lactation have late effects on intestinal sugar transport in their postweaning offspring.

Drozdowski LA, Iordache C, Clandinin MT, Todd ZS, Gonnet M, Wild G, Uwiera RR, Thomson AB.

J Nutr Biochem. 2008 Jan;19(1):49-60. Epub 2007 Jul 24.


Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical.

Wild GE, Drozdowski L, Tartaglia C, Clandinin MT, Thomson AB.

World J Gastroenterol. 2007 Jan 7;13(1):1-7. Review.


Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M; Onercept Study Group.

Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93. Epub 2006 Jun 22.


Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort.

Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Steinhart AH, Brant SR, Silverberg MS.

Am J Gastroenterol. 2006 May;101(5):1012-23.


Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19.

Tello-Ruiz MK, Curley C, DelMonte T, Giallourakis C, Kirby A, Miller K, Wild G, Cohen A, Langelier D, Latiano A, Wedemeyer N, Lander E, Schreiber S, Annese V, Daly MJ, Rioux JD.

Eur J Hum Genet. 2006 Jun;14(6):780-90.

Supplemental Content

Loading ...
Support Center